Lexaria Bioscience licenses DehydraTECH, a technology that improves how active ingredients are absorbed, to drug and consumer product makers. It last closed at $4.40 on Nov 17, down 0.90% on the day. LEXX reports earnings on Tue, Nov 24, 2026.
LEXX · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock is 12% above its 20 day and 20% above its 50 day average. It is 93% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 58). The nearest support is the Pivot at $4.33, and the nearest resistance the Pivot R1 at $4.47.
Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityNormal, 10.5%/day
Key levels
$21.6052 week high+390.9%
$8.51200 day average+93.4%
$6.22100 day average+41.4%
$4.79Swing high (Nov 10)+8.9%
$4.47Pivot R1+1.6%
$4.40Last close
$4.33Pivot−1.6%
$4.25Pivot S1−3.4%
$4.21Swing low (Aug 3)−4.3%
$3.8620 day average−12.3%
$3.5250 day average−20.0%
$2.4352 week low−44.8%
Indicators
RSI (14)
57.84
Middle of its range
Neutral
MACD
0.20
Above its signal line
Bullish
Stochastic
79.4
Middle of its range
Neutral
ADX (14)
18.6
No clear trend
Williams %R
-22.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
61.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+14.0%
Change over 10 sessions
Bullish
ATR (14)
$0.46
Typical daily range, 10.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 45.5%/day
Key levels
$21.6052 week high+390.9%
$8.51200 day average+93.4%
$6.22100 day average+41.4%
$4.79Swing high (Nov 10)+8.9%
$4.47Pivot R1+1.6%
$4.40Last close
$4.33Pivot−1.6%
$4.25Pivot S1−3.4%
$4.21Swing low (Aug 3)−4.3%
$3.8620 day average−12.3%
$3.5250 day average−20.0%
$2.4352 week low−44.8%
Indicators
RSI (14)
43.08
Middle of its range
Neutral
MACD
-1.71
Above its signal line
Bullish
Stochastic
16.9
Near the bottom of its range
Oversold
ADX (14)
10.9
No clear trend
Williams %R
-83.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-45.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+10.8%
Change over 10 sessions
Bullish
ATR (14)
$2.00
Typical daily range, 45.5% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LEXX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LEXX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Earnings in 6 daysSignals right before a report are less reliable. The report can override them.
November seasonalityHow LEXX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LEXX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LEXX is in one of them and how their past LEXX trades turned out.
Lexaria Bioscience is a biotechnology company based in Kelowna, British Columbia, Canada. It develops DehydraTECH, a technology that combines active ingredients with certain fatty acid rich oils so the body absorbs them more effectively. The technology can be used in tablets, capsules, oral suspensions, beverages and oral pouches. Lexaria licenses DehydraTECH to drug, nutraceutical and consumer product makers, who build it into their own products.